SOPHiA GENETICS (SOPH) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.20
- Estimate
- -$0.22
- Surprise
- +10.9%
- Score today
- 5.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
SOPHiA GENETICS (SOPH) reported a narrower loss than forecast — diluted EPS of -$0.20 against the -$0.22 estimate (a 10.9% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates SOPH Sell at 5.5/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +10.9% surprise compares with a +11.9% four-quarter average. Next scheduled report: 2026-11-03.
What argues against it
- Target reached (-4.2% upside)
- Quality below floor (3.5 < 4.0)
- Negative risk/reward — downside exceeds upside
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $8.68
- Price target
- $9.95
- Stop
- $8.04
- Upside to target
- +14.6%
Risk check: RSI 82 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
SOPH at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Health Information Services
- Market cap
- $736.4M
- P/E (fwd)
- -17.3
- 52-week range
- $3.10–$8.68
- Off 52-week high
- 0.0%
- RSI (14)
- 82
- Volume vs avg
- 0.88×
- Score today
- 5.5/10